News

Merck & Co. ($MRK) is betting on acquisitions to offset the looming revenue loss from the upcoming patent expiration of ...
Merck & Co., Inc. outshines Gilead Sciences, Inc. with stronger dividend growth, valuation metrics & PEGY ratio. Click for ...
Johnson & Johnson’s stock rose 2.4% in premarket trading, enough to pace the Dow Jones Industrial Average’s early gainers.
Merck is a massive company with strong fundamentals and underlying value at a heavily discounted price. Click here to find ...
Merck is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings dip.
Abbott Laboratories shares slumped Thursday after the drugmaker narrowed its full-year outlook, even as it posted better-than ...
In the latest trading session, Merck (MRK) closed at $79.29, marking a +1.29% move from the previous day. The stock exceeded ...
Valuation and Upside Potential. Currently, MRK stock trades at around $80, valuing the company at 3.2 times its trailing revenues. This falls below its three-year average price-to-sales (P/S ...
Merck (MRK) ended the recent trading session at $78.27, demonstrating a +1.46% swing from the preceding day's closing price. The stock exceeded the S&P 500, which registered a gain of 0.01% for ...
Global markets have been seesawing this week, as traders digest the latest trade tariff news. Overnight, Asia-Pacific markets ...
Merck (NYSE: MRK) stock lost 9.8% in May and plunged to its 52-week low of $73.31 a share after President Donald Trump signed an executive order directing drugmakers in the U.S. to cut the prices ...